Growth Hormone Resistance of Beta-cells
Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years to 59 Years
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * body mass index \>18.5kg/m2 and \<45.9kg/m2 * impaired fasting glucose \>/= 100mg/dL, \</= 126mg/dL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg/dL at two-hours) Exclusion Criteria: * pregnant, planning to become pregnant during the study, or breastfeeding * current diagnosis or history of type 1 or type 2 diabetes * use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * history of bariatric surgery * known, uncontrolled hypothyroidism * history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * current cancer or cancer that has been in remission less than 5 years * first degree relative with type 1 diabetes * evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * greater than 3% weight loss within three months of screening or engaged in regular (\>/= 3 days per week), continuous moderate- or high-intensity exercise of \>/= 30 min duration * mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
Study sites (1)
MO
- University of Missouri School of Medicine · Columbia, MO 65212Study coordinator · Study contact · 573-884-6852 · ahmc4@health.missouri.eduMore trials in Columbia